Napo Pharmaceuticals Inc.
San Francisco, CA Part of Jaguar Health, Inc.
- UEI
- GNMTLLK5JQE5
- CAGE
- 5DTK4
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
Parent
Jaguar Health, Inc.
FKLSBV7MMT97
-
Parent
Jaguar Health, Inc.
FKLSBV7MMT97
- SAM.gov registration date
- Physical address
- 200 Pine St Fl 4, San Francisco, CA 94104, USA
- Website
- napopharma.com
- Founded
- 2002
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $77,209 |
| FY2025 | $42,225 |
| FY2024 | $45,603 |
| FY2023 | $106,159 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $77,209 |
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Pharm - mytesi | Veterans Integrated Service Network 20 (VHA) | $77,209 | |
| Mytesi | Veterans Integrated Service Network 20 (VHA) | $42,225 | |
| Mytesi oral tabs | Veterans Integrated Service Network 20 (VHA) | $3,378 | |
| Mytesi | Veterans Integrated Service Network 20 (VHA) | $42,225 | |
| Mytesi 125MG tablet | Veterans Integrated Service Network 20 (VHA) | $41,047 |
Latest 5 listed here. See the rest on GovTribe.
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of crofelemer to treat vibrio cholerae | National Institutes of Health | $111,427 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Ascendis Pharma, Inc. | — | 325412 Pharmaceutical Preparation Manufacturing |
| Mirum Pharmaceuticals, Inc. | San Mateo, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Urogen Pharma Inc. | Princeton, NJ | 325414 Biological Product (except Diagnostic) Manufacturing |
| 60P | Washington, DC | 325412 Pharmaceutical Preparation Manufacturing |
| Incyte Corporation | Wilmington, DE | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Napo Pharmaceuticals Inc. is a pharmaceutical company and a subsidiary of Jaguar Health Inc. specializing in developing and supplying treatments for gastrointestinal disorders. The company provides federal contract services primarily to the Department of Veterans Affairs (VA), with a specific focus on delivering pharmaceutical products. Its core product, Mytesi (crofelemer), is a 125mg oral tablet designed to treat non-infectious diarrhea in adult HIV/AIDS patients receiving antiretroviral therapy. Registered in SAM.gov since April 1, 2009, the company is structured as a for-profit, corporate entity that manufactures pharmaceutical goods.
Through its federal contract awards, Napo Pharmaceuticals Inc. has consistently supplied Mytesi to VA healthcare facilities across the United States. All of its recent contract awards have been delivery orders issued by the Veterans Integrated Service Network 20, with contract values ranging from $3,378.02 to $42,225.25. The contracts are firm fixed-price delivery orders and are not designated as set-aside, indicating the company competes in open market procurement. Each contract is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), specifically Schedule 65 IB for drugs, pharmaceuticals, and hematology-related products, demonstrating the company's specialized pharmaceutical procurement capabilities.
Napo Pharmaceuticals Inc. holds a multiple-award Indefinite Delivery Vehicle (IDV) federal contract valued at $1,151,660, which runs from August 1, 2023, through July 31, 2028. This Federal Supply Schedule contract allows VA healthcare facilities nationwide to efficiently order Mytesi through pre-established pricing and procurement mechanisms. The IDV contract, awarded by the Veterans Integrated Service Network, covers drugs, pharmaceuticals, and hematology-related products. Task orders issued under this IDV are consistently focused on delivering Mytesi, supporting the VA's commitment to providing critical pharmaceutical products for veteran patients, with individual task order values typically ranging between $3,000 and $42,000.
Quick answers
Is Napo Pharmaceuticals Inc. registered in SAM.gov?
Yes. Napo Pharmaceuticals Inc.'s SAM.gov registration is active through June 25, 2027.
Which contract vehicles does Napo Pharmaceuticals Inc. hold?
Napo Pharmaceuticals Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Napo Pharmaceuticals Inc. received in federal contracts?
Federal contracts obligated $42,225 to Napo Pharmaceuticals Inc. in fiscal year 2025 and $271,196 in fiscal years 2023 through 2027.
What is Napo Pharmaceuticals Inc.'s most recent federal award?
Napo Pharmaceuticals Inc.'s most recent federal contract award is Pharm - mytesi (36C26026F0023), from Veterans Integrated Service Network 20 (VHA), on October 1, 2025.
On GovTribe
See Napo Pharmaceuticals Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors